Form 4: Merus CMO Cashes Out Options in Genmab Tender Offer

Merus N.V.'s Chief Medical Officer, Fabian Zohren, cashed out all his share options following Genmab's successful tender offer for Merus shares at $97.00 per share.

Summary

• Genmab A/S, through its wholly-owned subsidiary Genmab Holding II B.V., completed a tender offer for all issued and outstanding common shares of Merus N.V.
• The offer consideration for the tender was a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
• The purchaser accepted all validly tendered shares as of the Acceptance Time on December 12, 2025.
• Fabian Zohren, Merus N.V.'s Chief Medical Officer, had his share options cancelled pursuant to the Transaction Agreement.
• He received a cash payment for the cancelled options, calculated as the product of the amount by which the Offer Consideration ($97.00) exceeded the applicable exercise price per share and the aggregate number of shares underlying each option.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a tender offer and the profitable cash-out of executive equity incentives, which is a positive outcome for the selling shareholders and the reporting person. The event itself is a definitive corporate action, leading to a clear resolution for the company's public status.

Positives

• Merus N.V. shareholders who tendered their shares received a significant cash payment of $97.00 per share, representing a clear valuation for their holdings.
• Fabian Zohren, the Chief Medical Officer, received a substantial cash payout of over $10.5 million for his equity incentives, indicating a profitable realization of his options.
• The completion of the tender offer provides certainty for Merus N.V. shareholders and employees regarding the company's future ownership and strategic direction.

Negatives

• The cancellation of Fabian Zohren's share options means he no longer holds direct equity incentives in Merus N.V.
• Merus N.V. will cease to be an independent publicly traded entity following its acquisition by Genmab, potentially limiting future public investment opportunities in the company.

Future Outlook

The completion of the tender offer indicates that Merus N.V. will become a wholly-owned subsidiary of Genmab, with its common shares no longer publicly traded. This marks a transition from an independent public entity to a private subsidiary.

Industry Context

The acquisition of Merus N.V. by Genmab A/S is consistent with broader industry trends of consolidation in the biotechnology sector, where larger pharmaceutical and biotech companies acquire smaller firms to expand their product pipelines and technological capabilities, often targeting innovative platforms or promising drug candidates.

Stakeholder Impact

• Shareholders: Received a cash payment of $97.00 per share for their tendered Merus N.V. common shares.
• Employees (including Fabian Zohren): Equity incentives were cashed out, and the company will operate under new ownership, potentially impacting future compensation and organizational structure.
• Merus N.V. as an entity: Will become a private subsidiary of Genmab A/S, ceasing to be a publicly traded company.

Next Steps

• Payment of the Offer Consideration to shareholders who validly tendered their shares.
• Merus N.V. will transition to operating as a wholly-owned subsidiary of Genmab A/S.

Key Dates

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, Acquisition, Share Options, Insider Transaction, Form 4, Chief Medical Officer, Equity Compensation